Immunitybio, Inc. (IBRX) - Comprehensive Stock Analysis & Investment Research
Deep dive into Immunitybio, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Immunitybio, Inc. Investment Summary
When evaluating whether Immunitybio, Inc. (IBRX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Immunitybio, Inc. (IBRX) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $9 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.
Financial Performance Analysis
Our comprehensive financial analysis covers Immunitybio, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Immunitybio, Inc. along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Immunitybio, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Immunitybio, Inc. (Stock Symbol: IBRX) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about Immunitybio, Inc.'s leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Immunitybio, Inc....
Sector & Industry Analysis
In-depth sector dynamics and industry context for Immunitybio, Inc....
Revenue & Growth Analysis
Immunitybio, Inc. generates annual revenues of $165 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Immunitybio, Inc....
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Immunitybio, Inc....
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Immunitybio, Inc....
Strategic Market Position
Immunitybio, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.
Industry Competitive Landscape
Immunitybio, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company currently shows negative free cash flow of $-288 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.
Margin & Pricing Power Analysis
The company maintains a 99.3% gross margin which reflects strong pricing power and/or low direct production costs relative to revenue. Gross margins are only comparable within an industry, so read this level against the company's peers rather than the market as a whole.
Operating margin of -151.9% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.
Asset Utilization Efficiency
Asset turnover ratio of 0.26x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.
Financial Strength & Leverage
Current ratio of 5.72 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.